Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study

References

• European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011–2012. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf. Accessed March 14, 2018.
   Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208.
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
   PubMed Web of Science ®Google Scholar
• Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant gram-negative bacteria. J Antimicrob Chemother. 2010;65(Suppl 3):iii25–iii33.
   Web of Science ®Google Scholar
• Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122(6):7–15.
   PubMed Web of Science ®Google Scholar
• Nicolle LE. AMMI Canada Guidelines Committee* ACG. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16(6):349–360.
   PubMedGoogle Scholar
• Peña C, Cabot G, Gómez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis. 2015;60(4):539–548.
   PubMed Web of Science ®Google Scholar
• Mulet X, Cabot G, Ocampo-Sosa AA, et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother. 2013;57(11):5527–5535.
   PubMed Web of Science ®Google Scholar
• Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc. 2015;90(3):395–403.
   PubMed Web of Science ®Google Scholar
• Shaw E, Addy I, Stoddart M, et al. Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). BMJ Open. 2016;6(7):e011500.
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz N, Babitch T, Shaw E, et al. Risk factors for treatment failure and mortality among hospitalised patients with complicated urinary tract infection: a multicentre retrospective cohort study, RESCUING study group. Clin Infect Dis. Epub 2018 May 17.
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499.
   PubMed Web of Science ®Google Scholar
• International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed March 14, 2018.
   Google Scholar
• International Classification of Diseases, Tenth Revision, Clinical Modification, ICD-10-CM. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm. Accessed March 14, 2018.
   Google Scholar
• Tract CU. Guidance for Industry Complicated Urinary Tract Infections : Developing Drugs for Treatment Guidance for Industry Complicated Urinary Tract Infections: Developing Drugs for Treatment; 2012. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf. Accessed June 4, 2018.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Shigemura K, Arakawa S, Sakai Y, Kinoshita S, Tanaka K, Fujisawa M. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999–2003). Int J Urol. 2006;13(5):538–542.
   PubMed Web of Science ®Google Scholar
• Ferreiro LJ, Álvarez J, González L, et al. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: mortality and prognostic factors. Plos One. 2018;12(5):e0178178.
   Web of Science ®Google Scholar
• Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health. 2009;2(3):101–111.
   PubMedGoogle Scholar
• Tielen P, Narten M, Rosin N, et al. Genotypic and phenotypic characterization of Pseudomonas aeruginosa isolates from urinary tract infections. Int J Med Microbiol. 2011;301(4):282–292.
   PubMed Web of Science ®Google Scholar
• Surveillance Report. Surveillance of antimicrobial resistance in Europe 2016. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf. Accessed March 14, 2018.
   Google Scholar
• Ö K, Özger HS, Karas¸ahin EF, et al. Assessment of risk factors, treatment and hospital stay in complicated urinary tract infections in men caused by pseudomonas: a case-control study. J Urol Surg. 2017;44:48–52.
   Google Scholar
• Berrazeg M, Jeannot K, Ntsogo Enguéné VY, et al. Mutations in β-lactamase AmpC increase resistance of pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother. 2015;59(10):6248–6255.
   PubMed Web of Science ®Google Scholar
• Laudy AE, Róg P, Smolin´ska-Król K, et al. Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. PLoS One. 2017;12(6):e0180121.
   PubMed Web of Science ®Google Scholar
• Vazquez-Guillamet MC, Vazquez R, Micek ST, Kollef MH. Predicting resistance to piperacillin-tazobactam, cefepime and meropenem in septic patients with bloodstream infection due to gram-negative bacteria. Clin Infect Dis. 2017;65(10):1607–1614.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013;34(9):940–946.
   PubMed Web of Science ®Google Scholar
• Venier AG, Lavigne T, Jarno P, et al. Nosocomial urinary tract infection in the intensive care unit: when should Pseudomonas aeruginosa be suspected? Experience of the French national surveillance of nosocomial infections in the intensive care unit, Rea-Raisin. Clin Microbiol Infect. 2012;18(1):E13–E15.
   PubMed Web of Science ®Google Scholar
• Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis. 2009;48(5):580–586.
   PubMed Web of Science ®Google Scholar
• Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–268.
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–48.
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Shaw E, Padilla B, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect. 2013;19(10):962–968.
   PubMed Web of Science ®Google Scholar